Table 4.

Biomarker predicting AF in complete cohort (∑n = 81, AF n = 21).

Parameter	Univariate Regression Analysis		Multivariate Regression Analysis
	Hazard Ratio (95% Confidence Interval)	p	Hazard Ratio (95% Confidence Interval)	p
s-ST2 (ng/mL)	1.03 (0.99–1.07)	0.179
Galectin−3 (ng/mL)	1.33 (1.02–1.73)	0.04	1.20 (0.86–1.67)	0.27
miR−21	0.17 (0.04–0.74)	0.02	0.16 (0.04–0.7)	0.009
miR−29a	0.22 (0.06–0.78)	0.02	1.16 (0.03–52−2)	0.941
miR−133a	0.55 (0.2–1.45)	0.23
miR−146b	0.25 (0.08–0.74)	0.01	0.71 (0.01–64.3)	0.71
miR−328	0.21 (0.06–0.8)	0.02	1.33 (0.09–20.7)	0.44
NT-proBNP (ng/L)	1.002 (1.001–1.004)	0.003	1.002 (1.001–1.004)	0.006

miR—Micro ribonucleic acid, NTproBNP—N-terminal pro-brain natriuretic peptide, s-ST2—soluble ST2, ST2—suppression of tumorigenicity 2. Receiver operating characteristic (ROC) curve analysis presenting the predictive ability of miR−21, NT-proBNP and the combination of NT-proBNP and miR−21, are presented in Figure 5. Of note, the AUC is clearly enhanced by addition of miR−21 to NT-proBNP (AUC = 0.843) in comparison to NT-proBNP (AUC = 0.763) and miR−21 (AUC = 0.300) alone.